Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + rilpivirine + tenofovir disoproxil fumarate is a once-daily, oral fixed-dose antiretroviral combination for treatment of **human immunodeficiency virus type 1 infection**. It combines emtricitabine, a nucleoside reverse transcriptase inhibitor; tenofovir disoproxil fumarate, an orally bioavailable prodrug of the nucleotide reverse transcriptase inhibitor tenofovir; and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. The three agents inhibit HIV-1 reverse transcriptase through complementary active-site and allosteric mechanisms, suppressing viral replication. It is marketed by Gilead as Complera in the United States and Eviplera in Europe. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d637cfab-f1e8-4eb3-a1b3-f85ca3bec612))
- Brand names
- CompleraEviplera
- Other names
- emtricitabine + rilpivirine + tenofovir disoproxilemtricitabine/rilpivirine/tenofovir disoproxilemtricitabine/rilpivirine/tenofovir disoproxil fumarateFTC/RPV/TDFFTC/RPV/TFVrilpivirine/emtricitabine/tenofovir disoproxil fumarateRPV/FTC/TDFTDF/FTC/RPV
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on emtricitabine + rilpivirine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + rilpivirine + tenofovir disoproxil fumarate.